Publications by authors named "Eszter Dalma Palinkas"
Objective: To describe the potential clinical cardiotoxicity of oncological treatments in a cohort of consecutive patients with hypertrophic cardiomyopathy (HCM), systematically followed-up at two national referral centers for HCM. Cardiotoxicity relates to the direct effects of cancer-related treatment on heart function, commonly presenting as left ventricular contractile dysfunction. However, limited data are available regarding cardiotoxic effects on HCM as most studies have not specifically analyzed the effects of oncological treatment in HCM populations.
View Article and Find Full Text PDFArticle Synopsis
- Hypertrophic cardiomyopathy is a heart condition that runs in families and can cause problems like irregular heartbeats and heart failure.
- One major issue can happen when blood has trouble flowing out of the heart, making it work harder.
- Doctors can use different treatments like medications and special procedures to help improve the heart's function and make patients feel better.
This review aims to serve as a guide for clinical practice and to appraise the current knowledge on exercise stress echocardiography in the evaluation of intraventricular obstruction in HCM, in patients with cardiac syndrome X, in athletes with symptoms related to exercise, and in patients with normal left ventricular systolic function and exercise-related unexplained tiredness. The appearance of intraventricular obstruction while exercising is considered rare, and it usually occurs in patients with hypertrophy of the left ventricle. The occurrence of intraventricular obstruction when exercising has been evidenced in patients with hypertrophic cardiomyopathy, athletes, patients with cardiac syndrome X, patients with syncope or dizziness related to exercise, and patients with dyspnea and preserved ejection fraction.
View Article and Find Full Text PDFArticle Synopsis
- * Next Generation Sequencing (NGS) has made genetic data interpretation more intricate, necessitating collaboration between cardiologists and geneticists to assess genetic changes accurately.
- * Effective communication between healthcare providers and patients is crucial for addressing concerns and maximizing the benefits of genetic testing in managing HCM.
Article Synopsis
- - The study analyzed the causes of death in 161 hypertrophic cardiomyopathy (HCM) patients over a 20-year period, finding that 64% died from HCM-related issues, primarily heart failure, while 36% died from other causes.
- - Younger patients were more likely to experience sudden cardiac death (SCD), while those who died from heart failure often fell into older age groups, suggesting less availability of transplant options.
- - The modes of death varied by HCM disease stage, with SCD being more common in the early "classic" stage and heart failure deaths increasing significantly in later stages, highlighting a shift in mortality risk as the disease progresses.
Pulmonary congestion during Exercise stress Echocardiography in Hypertrophic Cardiomyopathy.
Int J Cardiovasc Imaging
December 2022
Article Synopsis
- A study evaluated the presence of B-lines, which indicate pulmonary congestion, in 128 patients with hypertrophic cardiomyopathy (HCM) during exercise stress echocardiography.
- Results showed that more patients had B-lines during exercise compared to at rest, with significant differences in factors like E/e' and systolic pulmonary arterial pressure (SPAP) between those with and without B-lines.
- The findings suggest that B-lines and SPAP are independent predictors of exercise-induced pulmonary congestion, highlighting the importance of using lung ultrasound in assessing HCM patients.
Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium most commonly caused by mutations in sarcomeric genes. We aimed to perform a nationwide large-scale genetic analysis of a previously unreported, representative HCM cohort in Hungary. A total of 242 consecutive HCM index patients (127 men, 44 ± 11 years) were studied with next generation sequencing using a custom-designed gene-panel comprising 98 cardiomyopathy-related genes.
View Article and Find Full Text PDFGenetic testing in children with hypertrophic cardiomyopathy (HCM) can modify clinical management and lifestyle counseling. However, predicting long-term outcome and response to management in individual patients remains challenging, because of the peculiar genetic heterogeneity of the disease in the pediatric age range. Children with HCM secondary to an inborn error of metabolism or malformation syndromes tend to have a worse outcome compared with those with the classic sarcomeric form.
View Article and Find Full Text PDFStress echo (SE) 2030 study is an international, prospective, multicenter cohort study that will include >10,000 patients from ≥20 centers from ≥10 countries. It represents the logical and chronological continuation of the SE 2020 study, which developed, validated, and disseminated the "ABCDE protocol" of SE, more suitable than conventional SE to describe the complex vulnerabilities of the contemporary patient within and beyond coronary artery disease. SE2030 was started with a recruitment plan from 2021 to 2025 (and follow-up to 2030) with 12 subprojects (ranging from coronary artery disease to valvular and post-COVID-19 patients).
View Article and Find Full Text PDFBackground: Sympathetic dysfunction can be evaluated by heart rate reserve (HRR) with exercise test.
Objectives: To determine the value of HRR in predicting outcome of patients with hypertrophic cardiomyopathy (HCM).
Methods: We enrolled 917 HCM patients (age = 49 ± 15 years, 516 men) assessed with exercise stress echocardiography (ESE) in 11 centres.